{"schema_version":"1","generated_at":"2026-11-05T23:03:07.591Z","data_as_of":null,"url":"https://www.findmykol.com/kol/meghan-liel","json_url":"https://www.findmykol.com/kol/meghan-liel/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"meghan-liel","name":"Meghan Liel","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Lafayette","state":"CO","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1235347410","openalex":"A5034858590"},"summary":"Meghan Liel is an Oncology physician. OpenAlex indexes 7 publications with 383 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":7,"cited_by_count":383,"h_index":7,"latest_activity_year":2015,"source":"works"},"prescribing":{"data_year":2024,"areas_total":7,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":51.1,"classes_total":7,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":16.7,"drugs":[{"name":"Ibrance","share_pct":41.5},{"name":"Tagrisso","share_pct":19.7},{"name":"Brukinsa","share_pct":12.2},{"name":"Kisqali","share_pct":10.9},{"name":"Imbruvica","share_pct":8.2},{"name":"Cabometyx","share_pct":7.5}],"max_beneficiaries":null},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":15.7,"drugs":[{"name":"Letrozole","share_pct":64.5},{"name":"Anastrozole","share_pct":27.5},{"name":"Exemestane","share_pct":8}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":22.5,"classes_total":4,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":10.6,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":28},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":5.5,"drugs":[{"name":"Ondansetron Odt","share_pct":58.3},{"name":"Ondansetron Hcl","share_pct":41.7}],"max_beneficiaries":17}]},{"area":"Nervous system","share_pct":9.4,"classes_total":4,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":5.1,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":20},{"class":"Opioid Agonist","setting":"prescribed","share_pct":1.5,"drugs":[{"name":"Oxycodone Hcl","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2021,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":7,"shown":5,"withheld":2,"matched_by":"OpenAlex author record","recent":[{"title":"Increased fracture rates in people with haemophilia: a 10‐year single institution retrospective analysis","year":2015,"journal":"British Journal of Haematology","source_url":"https://doi.org/10.1111/bjh.13312","status":"verified"},{"title":"The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption","year":2013,"journal":"Haemophilia","source_url":"https://doi.org/10.1111/hae.12195","status":"verified"},{"title":"Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency","year":2012,"journal":"British Journal of Haematology","source_url":"https://doi.org/10.1111/j.1365-2141.2012.09101.x","status":"verified"},{"title":"Reduced Bone Mineral Density in Factor VIII Deficient Mice and the Role of Inflammatory Cytokines","year":2011,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.v118.21.21.21","status":"verified"},{"title":"A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer","year":2007,"journal":"Cancer","source_url":"https://doi.org/10.1002/cncr.22545","status":"verified"}],"source":"works"},"contact":{"address_1":"280 EXEMPLA CIR","city":"Lafayette","state":"CO","zip":"800263370","phone":"303-338-4545","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1235347410","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":2}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-07-21","provider_certified":"2021-05-10","collected_at":"2026-11-05T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}